Robyn Karnauskas
Stock Analyst at Truist Securities
(1.89)
# 3,068
Out of 4,876 analysts
183
Total ratings
42.04%
Success rate
-1.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.61 | +177.01% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $277.13 | +7.53% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.35 | +40.24% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $79.10 | +39.06% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $110.67 | -25.00% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $182.31 | +15.19% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.81 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $126.08 | +169.67% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $2.17 | +1,098.16% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $0.74 | +842.00% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $521.00 | +117.85% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.69 | +491.72% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.62 | +243.51% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $16.54 | +347.40% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.39 | +101.93% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.10 | +198.14% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $7.95 | +528.93% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $775.45 | +9.61% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $441.30 | +15.11% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $24.19 | +48.82% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $49.84 | -49.84% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.77 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $55.17 | +153.76% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.09 | +174,521.65% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.04 | +573.08% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $13.86 | +296.83% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.70 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $22.69 | +1,310.31% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.71 | +304.31% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.32 | +26,150.77% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.61
Upside: +177.01%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $277.13
Upside: +7.53%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.35
Upside: +40.24%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $79.10
Upside: +39.06%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $110.67
Upside: -25.00%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $182.31
Upside: +15.19%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.81
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $126.08
Upside: +169.67%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $2.17
Upside: +1,098.16%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.74
Upside: +842.00%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $521.00
Upside: +117.85%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.69
Upside: +491.72%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.62
Upside: +243.51%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $16.54
Upside: +347.40%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.39
Upside: +101.93%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $16.10
Upside: +198.14%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $7.95
Upside: +528.93%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $775.45
Upside: +9.61%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $441.30
Upside: +15.11%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $24.19
Upside: +48.82%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $49.84
Upside: -49.84%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.77
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $55.17
Upside: +153.76%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.09
Upside: +174,521.65%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.04
Upside: +573.08%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $13.86
Upside: +296.83%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.70
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $22.69
Upside: +1,310.31%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.71
Upside: +304.31%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.32
Upside: +26,150.77%